Among critically ill patients with hypoactive or hyperactive delirium, does administration of the antipsychotic medications haloperidol or ziprasidone improve the number of days alive without delirium or coma when compared to placebo?
Among critically ill patients with hypoactive or hyperactive delirium, administration of the antipsychotic medications haloperidol or ziprasidone did not imprive the number of days alive without delirium or coma when compared to placebo.
The incidence of delirium within the ICU has been cited to be 30% however can reach much higher incidences in certain ICU populations particularly in conjunction with organ failure or mechanical ventilation. Delirium, similar to non-ICU patients, is associated with increased mortality, prolonged mechanical ventilation, and prolonged ICU stays. Many trials to date have looked at the use of antipsychotic therapy in both prevention of delirium as well as reducing the length of delirium.HOPE-ICU (2013) tested haloperidol, a typical antipsychotic, in preventing delirium without evidence of shortening duration or incidence of delirium. A pilot study by Devlin et al. (2010) identified the potential for the atypical antipsychotic, quetiapine, to reduce duration of delirium and increase rates of hospital discharge when added to haloperidol. Given these varied findings, the role of antipsychotic therapy in management of ICU-related delirium was unclear.
Published in 2018, the Modifying the Impact of ICU-Associated Neurological Dysfunction–USA (MIND-USA) trial compared haloperidol (brand name Haldol, typical antipsychotic) and ziprasidone (brand name Geodon, atypical antipsychotic) against placebo therapy for the treatment of delirium over a 14-day period. This study was the first to directly compare a typical antipsychotic medication with an atypical antipsychotic medication and a placebo-controlled group in delirium treatment. The study had a heavy predominance of hypoactive delirium patients (90%). There was no benefit seen in the primary outcome of days alive without delirium seen in either antipsychotic therapy group compared to placebo. Subgroup analysis did not reveal a decreased requirement of sedation administration despite antipsychotic therapy.
The major limitation in this study is the high proportion of participants with hypoactive delirium, who may have been less likely to receive a benefit from the study medications. The lack of consistent efficacy of antipsychotic medication in ICU-related delirium may be attributed to a poorly understood mechanism of delirium in critically ill patients who do not simply have an excess of neurological dopamine, which would respond to traditional dopamine-blockade therapy. Despite the negative result, it is feasible that antipsychotics may remain beneficial for particular groups of ICU patients who are either acutely agitated or suffering from delirium-related hallucinations or delusions.
As of November 2018, no guidelines have been published that reflect the results of this trial.
- Multicenter, double-blind, randomized, placebo-controlled trial
- Haloperidol (n=192)
- Ziprasidone (n=190)
- Placebo (n=184)
- Setting: 16 hospitals in the US
- Enrollment: 2011-2017
- Follow-up: 14-day intervention period with 90 days of follow-up
- Analysis: Intention-to-treat
- Primary outcome: Days alive without delirium or coma
- Age >18 years
- Medical/surgical ICU admission
- Requiring either NIPPV/Mechanical ventilation, vasopressors, or intra-aortic balloon pump
- Objectively confirmed delirium using the CAM-ICU
- Severe cognitive impairment at baseline
- High risk of medication side effects (Pregnant, breast-feeding, history of torsades, QTc >550ms at baseline, history of neuroleptic malignant syndrome, or allergy to trial drugs)
- Pre-existing treatment with antipsychotic medication
- Allergy to a study medication
- Moribund state
- Rapidly resolving organ failure
- Barriers to follow-up
Baseline characteristics from haloperidol group
- Demographics: Age 61 years, female sex 44%, white race 85%, black race 12%
- Delirium type: Hyperactive 10%, hypoactive 90%
- IQCODE score (to determine pre-existing dementia, out of 5, higher is worse): 3.0
- Admission diagnosis: ARDS 23%, sepsis 22%, 'airway protection' 24%, COPD/asthma/other pulmonary disorder 10%, surgery 7%, HF MI or arrhythmia 3%, cirrhosis or liver failure 2%, seizure or neurological disease 2%, other 7%
- Shock at admission: 30%
- Surgical ICU 27%
- Median APACHE II score: 28.5
- Median Charlson comorbidity score: 2
- Ventilation: Invasive 93%, noninvasive 4%
- Median (IQR) ICU days prior to admission: 2.4 (1.5-3.4)
- Randomization to an arm:
- Haloperidol: Haloperidol 1.25mg (>70 years old) or 2.5mg (<70 years old) IV q12h prn for 14 days or until discharged from ICU. Uptitrated if persistent delirium up to 20mg per day, downtitrated if no delirium.
- Ziprasidone: Ziprasidone 2.5mg (>70 years old) or 5mg (<70 years old) IV q12h prn for 14 days or until discharged from ICU. Uptitrated if persistent delirium up to 40mg per day, downtitrated if no delirium.
- Patients were assessed every 12 hours for delirium using CAM-ICU and Richmond Agitation-Sedation Scale.
- If no delirium for 2 assessments, then half dose of antipsychotic.
- If no delirium for 4 assessments, then hold antipsychotic therapy.
- Stop if the patient develops torsades, NMS, DRESS, or new structural brain disease resulting in decreased level of consciousness
Placebo vs. haloperidol vs. ziprasidone
- Median days Alive without Delirium or Coma
- Adjusted days: 8.5 (95% CI 5.6, 9.9) vs. 7.9 (4.4, 9.6) vs. 8.7 (5.9, 10.0)
- The primary outcome was considered the adjusted analysis. Other day counts are unadjusted. All ORs are adjusted. These were adjusted for several covariates, detailed on page 8 of the supplementary appendix.
- Unadjusted days: 7 (IQR 0-11) vs. 8 (0-11) vs. 8 (2-11)
- Overall P=0.26
- Haloperidol vs. placebo: OR 0.88 (95% CI 0.64-1.21)
- Ziprasidone vs. placebo: OR 1.04 (95% CI 0.73-1.48)
For simplicity, IQRs for the remaining results are in Table 2 of the manuscript. Days are unadjusted and ORs are adjusted as described above.
- Median days with delirium
- 4 vs. 4 vs. 4
- Haloperidol vs. placebo: OR 1.12 (95% CI 0.86-1.46)
- Ziprasidone vs. placebo: OR 4.0 (95% CI 0.69-1.51)
- Median days with hyperactive delirium
- 0 vs. 0 vs. 0
- Haloperidol vs. placebo: OR 1.18 (95% CI 0.86-1.61)
- Ziprasidone vs. placebo: OR 1.09 (95% CI 0.70-1.70)
- Median days to freedom from mechanical ventilation
- 3 vs. 2 vs. 3
- Haloperidol vs. placebo: OR 0.92 (95% CI 0.71-1.19)
- Ziprasidone vs. placebo: OR 0.96 (95% CI 0.74-1.15)
- Median days to ICU discharge
- 5 vs. 5 vs. 6
- Haloperidol vs. placebo: OR 0.95 (95% CI 0.81-1.12)
- Ziprasidone vs. placebo: OR 1.02 (95% CI 0.88-1.17)
- 30-day mortality
- 27% vs. 26% vs. 28%
- Haloperidol vs. placebo: OR 1.03 (95% CI 0.73-1.46)
- Ziprasidone vs. placebo: OR 1.07 (95% CI 0.77-1.47)
- 90-day mortality
- 34% vs. 38% vs. 34%
- Haloperidol vs. placebo: OR 1.17 (95% CI 0.99-1.40)
- Ziprasidone vs. placebo: OR 1.02 (95% CI 0.79-1.30)
- 11% vs. 11% vs. 12%
- Prolonged QTc
- 1% vs. 1% vs. 2%
- Torsades des pointes
- 0% vs. 0% vs. 0%
- 0% vs. 0% vs. 0%
- The high proportion with hypoactive delirium (90%) may have been less likely to benefit from antipsychotic medications compared to hyperactive delirium patients.
- The use of ziprasidone in the ICU population is not as widespread compared to the atypical antipsychotic, quetiapine.
National Institutes of Health and the VA Geriatric Research Education and Clinical Center
- Salluh JI et al. Delirium epidemiology in critical care (DECCA): an international study. Crit Care 2010. 14:R210.
- Ely EW et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004. 291:1753-62.
- Page VJ et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2013. 1:515-23.
- Devlin JW et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit. Care Med. 2010. 38:419-27.
- Supplementary appendix